Tunlametinib Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Solid Cancers
Tianjin Medical University Second Hospital15 enrolled1 locationNCT07170293
Recruiting
Phase 2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University40 enrolled1 locationNCT06970353